NCT07428369 2026-02-23
LINKER-MM8
Regeneron Pharmaceuticals
Phase 2/3 Not yet recruiting
Clinical Trials
11 trialsNCT07355283 2026-01-27
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3 Not yet recruiting
NCT07341867 2026-01-14
Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype
Dana-Farber Cancer Institute
Phase 1 Not yet recruiting
NCT07334535 2026-01-13
Isa-VRD in TIE HRMM
Peking Union Medical College Hospital
Phase 4 Not yet recruiting
NCT07299149 2025-12-23
ZGR in TN FL
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07299331 2025-12-23
Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma
Zhengzhou University
Phase NA Not yet recruiting
NCT07285239 2025-12-16
PrE1005
PrECOG, LLC.
Phase 3 Not yet recruiting
NCT07261163 2025-12-03
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Not yet recruiting
NCT07133776 2025-08-21
Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.
The Affiliated Hospital of Xuzhou Medical University
Phase 1/2 Not yet recruiting
NCT06665217 2025-08-14
G-Pola-ZLP in Diffuse Large B-Cell Lymphoma
Navy General Hospital, Beijing
Phase 2 Not yet recruiting
NCT06931704 2025-04-23
IFM 2024_06
Nantes University Hospital
Phase 2 Not yet recruiting